TY - JOUR
T1 - Clinical predictive factors of long-term survival after curative resection of pancreatic cancer
T2 - a retrospective study
AU - Nakano, Yutaka
AU - Kitago, Minoru
AU - Shinoda, Masahiro
AU - Abe, Yuta
AU - Yagi, Hiroshi
AU - Hibi, Taizo
AU - Takeuchi, Ayano
AU - Aiura, Koichi
AU - Itano, Osamu
AU - Kitagawa, Yuko
N1 - Funding Information:
Yuko Kitagawa has received research funding from Kyowa Hakko Kirin Co., Ltd., Yakult Honsha Co., Ltd., Eli Lilly Japan K.K., and Taiho Pharmaceutical Co., Ltd. The remaining authors have no conflicts of interest to disclose.
Publisher Copyright:
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2017/10
Y1 - 2017/10
N2 - Pancreatic ductal adenocarcinoma (PDAC) continues to have the poorest prognosis of all gastrointestinal malignancies, even after the tumor has been completely resected. However, only a proportion of patients achieve 5-year survival after resection. The factors predictive of achieving 5-year survival remain unclear. The aim of this study was to investigate the pre- and postoperative clinicopathological characteristics of PDAC patients with a >5-year survival after curative resection. We retrospectively reviewed patients who underwent pancreatectomy for PDAC between January 1995 and December 2011. Logistic regression analysis was performed to determine the predictive factors for 5-year survival. One hundred and fifty-one patients were enrolled, including 38 patients with 5-year survival (actual 5-year survival rate, 25.2%). The independent preoperative factors predictive of achieving 5-year survival included serum albumin levels (odds ratio [OR]: 5.06, 95.0% confidence interval [CI]: 1.49–17.19; P = 0.009) and neoadjuvant chemoradiotherapy (OR: 3.02, 95.0% CI: 1.00–9.08; P = 0.049). Venous infiltration (OR: 2.99, 95.0% CI: 1.09–8.25; P = 0.034), liver recurrence (OR: 0.17, 95.0% CI: 0.04–0.69; P = 0.013), and perioperative portal vein infusion chemotherapy (OR: 3.06, 95.0% CI: 1.09–8.25; P = 0.028) were found to be independent postoperative predictive factors for achieving 5-year survival. Serum albumin levels could be a biomarker for predicting the prognosis of PDAC patients after curative resection. Liver recurrence and perioperative portal vein infusion chemotherapy were independent postoperative factors, suggesting that perioperative portal vein infusion chemotherapy could be promising for improving the survival rate of PDAC patients after curative resection.
AB - Pancreatic ductal adenocarcinoma (PDAC) continues to have the poorest prognosis of all gastrointestinal malignancies, even after the tumor has been completely resected. However, only a proportion of patients achieve 5-year survival after resection. The factors predictive of achieving 5-year survival remain unclear. The aim of this study was to investigate the pre- and postoperative clinicopathological characteristics of PDAC patients with a >5-year survival after curative resection. We retrospectively reviewed patients who underwent pancreatectomy for PDAC between January 1995 and December 2011. Logistic regression analysis was performed to determine the predictive factors for 5-year survival. One hundred and fifty-one patients were enrolled, including 38 patients with 5-year survival (actual 5-year survival rate, 25.2%). The independent preoperative factors predictive of achieving 5-year survival included serum albumin levels (odds ratio [OR]: 5.06, 95.0% confidence interval [CI]: 1.49–17.19; P = 0.009) and neoadjuvant chemoradiotherapy (OR: 3.02, 95.0% CI: 1.00–9.08; P = 0.049). Venous infiltration (OR: 2.99, 95.0% CI: 1.09–8.25; P = 0.034), liver recurrence (OR: 0.17, 95.0% CI: 0.04–0.69; P = 0.013), and perioperative portal vein infusion chemotherapy (OR: 3.06, 95.0% CI: 1.09–8.25; P = 0.028) were found to be independent postoperative predictive factors for achieving 5-year survival. Serum albumin levels could be a biomarker for predicting the prognosis of PDAC patients after curative resection. Liver recurrence and perioperative portal vein infusion chemotherapy were independent postoperative factors, suggesting that perioperative portal vein infusion chemotherapy could be promising for improving the survival rate of PDAC patients after curative resection.
KW - Achieving 5-year survival
KW - neoadjuvant chemoradiotherapy
KW - perioperative portal vein infusion chemotherapy
KW - predictive factors
KW - preoperative serum albumin
UR - http://www.scopus.com/inward/record.url?scp=85030862590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030862590&partnerID=8YFLogxK
U2 - 10.1002/cam4.1178
DO - 10.1002/cam4.1178
M3 - Article
C2 - 28925039
AN - SCOPUS:85030862590
SN - 2045-7634
VL - 6
SP - 2278
EP - 2286
JO - Cancer Medicine
JF - Cancer Medicine
IS - 10
ER -